HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

IRMD

IRADIMED CORPORATION (NASDAQ)

Healthcare — Medical Devices

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.

None 2 analysts
$98.04
+$2.48 (+2.60%)
Target: $118.00 (20.4%)
Sign in to add IRMD to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$1.25B
P/E Ratio (TTM)53.57
Forward P/E41.63
EPS (TTM)$1.83
Dividend Yield0.82%
Profit Margin27.37%
Revenue Growth12.60%
ROE25.04%
Debt/Equity-
Recommendation None
Analyst Target$118.00
Analysts2
Indexes NASDAQ

Technical Indicators

RSI (14)56.0
Beta0.92
SMA 20-
SMA 40-
52-Week High$107.90
52-Week Low$55.11
50-Day Avg$90.36
200-Day Avg$90.92
Avg Volume132.9K
Volume154.0K

Performance Analysis

BULLISH

IRMD shows predominantly bullish signals based on its fundamentals and technicals.

+ Showing strength at 81% of its 52-week range.
+ RSI at 56.0 shows positive momentum.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
- P/E of 53.6 is elevated — the market expects high growth or it may be overvalued.
~ Modest revenue growth of 12.6% year-over-year.
+ Healthy profit margin of 27.4%.
~ Wall Street consensus is "none" from 2 analysts.
+ Average analyst target of $118.00 implies 20.4% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:15 UTC

Back to Screener Export Report